EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a Recombinant Outer Membrane Vesicles (OMVs)‐Based Vaccine Against Helicobacter pylori Infection in Mice

Qiong Liu, Biaoxian Li, Jinrong Ma, Xiao Lei, Junpeng Ma, Yanyan Da, Zhiyong Zhou, Jiaqi Tao, Xinyi Ren, Ting Zeng, Zhiting Xie, Haiyan Lin und 11 weitere

Journal of Extracellular Vesicles · 2025-05 · 14 (5)

DOI: 10.1002/jev2.70085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 27.05.2025. Verfasst von Qiong Liu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Bacterial Vaccines, Extracellular Vesicles. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Project for high and talent of Science and Technology Innovation in Jiangxi "double thousand plan", The start-up fund from the First Affiliated Hospital of Nanchang University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current vaccine development for Helicobacter pylori ( H. pylori ) still faces challenges of weak immune responses stimulated by existing antigens and a lack of safe adjuvants. The modification of the lipopolysaccharide (LPS) structure by H. pylori is an important mechanism involved in its immune escape. In this study, we developed a novel recombinant vaccine candidate against H. pylori infection by knocking down the key genes (lpxE, lpxF and futB) of LPS modification and employing the bacterial outer membrane vesicles (OMVs) as a vector for delivering UreB, VacA and CagA antigens, and then evaluated its safety and immune protective efficacy in vitro and in vivo mouse model. We measured the antibody and cytokine productions, detected the subtypes of immune cells, and examined the histopathological changes in mice from the control and various experimental groups. We revealed that this OMV‐based recombinant vaccine candidate could induce specific humoral immune responses and a Th1/Th2/Th17 mixed immune response, with Th17 being predominant, and markedly protect the mice from H. pylori infection. Our findings suggest that the OMVs with the genetically engineered LPS may function as a vector for delivering recombinant antigens and safe adjuvants for the development of novel vaccine candidates against H. pylori infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriBacterial VaccinesExtracellular VesiclesBacterial Outer MembraneAnimalsMiceFemaleVaccines, SyntheticAntigens, BacterialMice, Inbred BALB CLipopolysaccharides

Stichwörter der Autor:innen

H. pyloriLPSOMVsrecombinant vaccine

Substanzen

Bacterial VaccinesVaccines, SyntheticAntigens, BacterialLipopolysaccharides

Autor:innen und Institutionen

  • Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Medical Microbiology, School of Basic Medical Sciences, Jiangxi Medcial College, Nanchang University, Nanchang, China.
  • Jiangxi Provincial Center for Advanced Diagnostic Technology and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Medical Genetics, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

ORCID-Profile: Chengsheng Zhang

Förderung

  • Project for high and talent of Science and Technology Innovation in Jiangxi "double thousand plan"
  • The start-up fund from the First Affiliated Hospital of Nanchang University
  • National Natural Science Foundation of China
  • The fund from School of Basic Medical Sciences, Nanchang University

Zitieren

APA

Liu, Q., Li, B., Ma, J., Lei, X., Ma, J., Da, Y., Zhou, Z., Tao, J., Ren, X., Zeng, T., Xie, Z., Lin, H., Jin, Z., Wan, Y., Zhang, L., Lai, D., Guo, Y., Li, J., Shang, Y., …, & Zhang, C. (2025). Development of a Recombinant Outer Membrane Vesicles (OMVs)‐Based Vaccine Against Helicobacter pylori Infection in Mice. Journal of Extracellular Vesicles, 14(5). https://doi.org/10.1002/jev2.70085

Vancouver

Liu Q, Li B, Ma J, Lei X, Ma J, Da Y, et al. Development of a Recombinant Outer Membrane Vesicles (OMVs)‐Based Vaccine Against Helicobacter pylori Infection in Mice. Journal of Extracellular Vesicles. 2025;14(5). doi:10.1002/jev2.70085

BibTeX
@article{Liu2025,
  author = {Liu, Qiong and Li, Biaoxian and Ma, Jinrong and Lei, Xiao and Ma, Junpeng and Da, Yanyan and Zhou, Zhiyong and Tao, Jiaqi and Ren, Xinyi and Zeng, Ting and Xie, Zhiting and Lin, Haiyan and Jin, Zihui and Wan, Yi and Zhang, Liang and Lai, Donglin and Guo, Yaping and Li, Jing and Shang, Yinpan and Shen, Lu and Tao, Ziwei and Gong, Tian and Zhang, Chengsheng},
  title = {Development of a Recombinant Outer Membrane Vesicles (OMVs)‐Based Vaccine Against Helicobacter pylori Infection in Mice},
  journal = {Journal of Extracellular Vesicles},
  year = {2025},
  volume = {14},
  number = {5},
  doi = {10.1002/jev2.70085}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche